| 查看: 467 | 回复: 0 | |||
iamwentworth新虫 (初入文坛)
|
[交流]
Postdoc available at UW-Madison, vascular biology or retinal degeneration
|
|
Postdoctoral Researcher#1: Madison, WI, United States Title: Postdoctoral Researcher Contact: University of Wisconsin Madison Salary: NIH standard Percent_Time: 100% Begin_EndDates: Immediate opening, available until filled Contact_Name: Lian-Wang Guo, PhD Contact_Email: Lianwangguo@wisc.edu We are looking for a motivated postdoc researcher to study vascular disease with a focus on BET epigenetic readers, a novel regulator in vascular stenosis. Our research team has published in PNAS, EBioMedicine, J Controlled Release, Circulation CVI, and Stem Cells. Guo lab research topics include molecular and cellular disease mechanisms as well as translational applications using nanoparticles. Ph.D. or M.D. in molecular biology/biochemistry and cell biology or related biomedical field is required. Experiences in Co-IP, animal models, immunohistochemistry and pathology are preferred. The incumbent will join a group of scientists who value multidisciplinary and collaborative approaches to address fundamental questions underlying human diseases. Job duties will include designing and conducting experiments, participating in manuscript and grant preparation, and training junior researchers. Please send curriculum vitae to: Lian-Wang Guo, PhD., Lianwangguo@wisc.edu Postdoctoral Researcher#2: Madison, WI, United States Title: Postdoctoral Researcher Contact: University of Wisconsin Madison Salary: NIH standard Percent_Time: 100% Begin_EndDates: Immediate opening, available until filled Contact_Name: Lian-Wang Guo, PhD Contact_Email: Lianwangguo@wisc.edu The Guo Lab at the University of Wisconsin has an immediate opening for a postdoctoral fellow. The talented individual will join a dynamic team aiming to better understand the pathobiology of retinal degenerative diseases such as macular degeneration. The projects focus on the investigation of novel signaling pathways in retinal epigenetic and metabolic regulations. The candidate must be motivated and capable of working independently yet collaboratively, and will enjoy the liberty to choose research directions. Skills should include quantitative RT-PCR, Western blotting, immunoprecipitation, multi-color flow cytometry, microscopy, and cell signaling. Prior experience in vision research and animal models is preferred but not required. Please send curriculum vitae to: Lian-Wang Guo, PhD., Lianwangguo@wisc.edu Guo Lab research summary Treatments for cardiovascular disease, including angioplasty and bypass, frequently fail primarily because of the transition of normal vascular smooth muscle cells to a disease state. We have recently identified a molecular switch that, when pharmacologically turned off, halts this disease-prone cellular transition. We are conducting in-depth research on this exciting finding, which may lead to improved methods for treating recurrent vascular disease. We are focusing on the bromo and extraterminal (BET) family of proteins, termed epigenetic “readers”. In response to pathogenic stimuli, BET proteins couple with cell type- or cell state-specific transcription factors to activate the expression of a select set of genes which in concert drive cellular transition to a disease state. We are working to differentiate the functions of the various BET proteins and bromo-domains in smooth muscle cell pathogenic transition, and to identify the key transcription factors that are governed by BET proteins. To this end, we are making use of the CRISPR/Cas9 technology for knockout and mutagenesis, and ChIPseq and RNAseq for genome wide analyses. In parallel, Dr. Guo’s laboratory is exploiting the potential of an endogenous neuroprotective pathway, the Sigma-1 receptor chaperone, in retinal neurons against cell death. We wish our research will produce new knowledge critical for effective treatment of blinding retinal diseases, or in a broader sense, neurodegenerative diseases. For translational medicine, Dr. Guo’s lab is collaborating with bioengineering experts Dr. William Murphy and Dr. Sarah Gong and vascular surgeon Dr. Craig Kent to develop targeted drug delivery platforms. |
回复此楼» 猜你喜欢
心脉受损
已经有8人回复
-
之前让一硕士生水了7个发明专利，现在这7个获批发明专利的维护费可从哪儿支出哈？
已经有9人回复
-
博士申请都是内定的吗？
已经有8人回复
-
博士读完未来一定会好吗
已经有32人回复
-
读博
已经有5人回复
-
投稿精细化工
已经有4人回复
-
高职单位投计算机相关的北核或SCI四区期刊推荐，求支招！
已经有4人回复
-
导师想让我从独立一作变成了共一第一
已经有9人回复
-
Springer期刊投稿求助
已经有4人回复
